Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Aldolase B

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Aldolase B. Displaying page 1 of 1.
    EudraCT Number: 2023-000033-33 Sponsor Protocol Number: 83631 Start Date*: 2023-05-03
    Sponsor Name:Maastricht University
    Full Title: Short-term safety and efficacy of ketohexokinase inhibition in patients with hereditary fructose intolerance.
    Medical condition: Hereditary fructose intolerance
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10019878 Hereditary fructose intolerance PT
    20.1 10010331 - Congenital, familial and genetic disorders 10017397 Fructose intolerance hereditary LLT
    21.0 10027433 - Metabolism and nutrition disorders 10072104 Fructose intolerance PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001277-23 Sponsor Protocol Number: ARGX-113-2007 Start Date*: 2022-10-26
    Sponsor Name:argenx BV
    Full Title: A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Phar...
    Medical condition: Active Idiopathic Inflammatory Myopathy (IIM)
    Disease: Version SOC Term Classification Code Term Level
    24.1 10028395 - Musculoskeletal and connective tissue disorders 10085970 Idiopathic inflammatory myopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing) LT (Ongoing) SE (Ongoing) DE (Ongoing) HU (Ongoing) IE (Ongoing) AT (Ongoing) ES (Ongoing) PT (Ongoing) IT (Ongoing) SK (Ongoing) PL (Ongoing) BG (Ongoing) GR (Ongoing) CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002269-77 Sponsor Protocol Number: IM101611 Start Date*: 2017-08-07
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC with Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in ...
    Medical condition: Idiopathic Inflammatory Myopathy (IIM; eg, Dermatomyositis [DM], Polymyositis [PM], autoimmune necrotizing myopathy)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10042753 Symptomatic inflammatory myopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) SE (Completed) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002605-22 Sponsor Protocol Number: KZR-616-003 Start Date*: 2020-01-28
    Sponsor Name:Kezar Life Sciences, Inc.
    Full Title: A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients with Active Polymyositis or Dermatomy...
    Medical condition: Autoimmune Disorders Polymyositis and Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10003816 Autoimmune disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003277-15 Sponsor Protocol Number: 8400-211 Start Date*: 2016-09-02
    Sponsor Name:Idera Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients with Dermatomyositis
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:11:22 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA